WO2015179258A3 - Mri-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening - Google Patents

Mri-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening Download PDF

Info

Publication number
WO2015179258A3
WO2015179258A3 PCT/US2015/031278 US2015031278W WO2015179258A3 WO 2015179258 A3 WO2015179258 A3 WO 2015179258A3 US 2015031278 W US2015031278 W US 2015031278W WO 2015179258 A3 WO2015179258 A3 WO 2015179258A3
Authority
WO
WIPO (PCT)
Prior art keywords
region
brain barrier
bbb
brain
blood
Prior art date
Application number
PCT/US2015/031278
Other languages
French (fr)
Other versions
WO2015179258A2 (en
Inventor
Piotr WALCZAK
Monica PEARL
Miroslaw JANOWSKI
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201461994880P priority Critical
Priority to US61/994,880 priority
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2015179258A2 publication Critical patent/WO2015179258A2/en
Publication of WO2015179258A3 publication Critical patent/WO2015179258A3/en
Priority claimed from US16/428,905 external-priority patent/US20190350486A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the blood-brain barrier (BBB) at an isolated region by locally administering an effective amount of a hyperosmolar agent at said region using a catheter, followed by administering a therapeutically effective amount of a therapeutic agent. The step of disrupting the BBB is carried out with non-invasive MR (magnetic resonance) imaging with a contrast agent to visualize local parenchymal transcatheter perfusion at said isolated BBB region thereby indicating that the BBB region is compromised. The method of the invention allows for highly precise drug delivery to the brain through blood brain barrier disruption at specifically controlled regions.
PCT/US2015/031278 2014-05-17 2015-05-17 Mri-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening WO2015179258A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461994880P true 2014-05-17 2014-05-17
US61/994,880 2014-05-17

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/311,696 US10478120B2 (en) 2014-05-17 2015-05-17 MRI-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening
US16/428,905 US20190350486A1 (en) 2014-05-17 2019-05-31 Mri-guided opening of blood-brain barrier

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/311,696 A-371-Of-International US10478120B2 (en) 2014-05-17 2015-05-17 MRI-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening
US16/428,905 Continuation-In-Part US20190350486A1 (en) 2014-05-17 2019-05-31 Mri-guided opening of blood-brain barrier

Publications (2)

Publication Number Publication Date
WO2015179258A2 WO2015179258A2 (en) 2015-11-26
WO2015179258A3 true WO2015179258A3 (en) 2016-01-21

Family

ID=54554949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/031278 WO2015179258A2 (en) 2014-05-17 2015-05-17 Mri-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening

Country Status (2)

Country Link
US (1) US10478120B2 (en)
WO (1) WO2015179258A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7520860B2 (en) 2005-04-13 2009-04-21 Marie G. Johnson Detection of coronary artery disease using an electronic stethoscope
WO2019044078A1 (en) * 2017-08-28 2019-03-07 富士フイルム株式会社 Brain image normalization device, method, and program
WO2019044228A1 (en) * 2017-08-28 2019-03-07 富士フイルム株式会社 Medical image processing device, method, and program
WO2020206281A1 (en) * 2019-04-04 2020-10-08 Northwestern University Improved delivery of drug therapy to the cns by ultrasound-based opening of the blood-brain barrier

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038086A1 (en) * 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
US20100172842A1 (en) * 2007-05-16 2010-07-08 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Assessment of blood-brain barrier disruption
US20110318431A1 (en) * 2008-12-30 2011-12-29 Endogenx Pharmaceutical Compositions and Methods of Treating Neurological Insults
US20130158387A1 (en) * 2010-08-30 2013-06-20 Koninklijke Philips Electronics N.V. Mri thermal imaging of water tissue and fat tissue using transverse relaxometry data and proton resonance frequency shift data

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW319763B (en) * 1995-02-01 1997-11-11 Epix Medical Inc
US20060024359A1 (en) * 1995-06-07 2006-02-02 Walker Jeffrey P Drug delivery system and method
US7674457B2 (en) * 2003-12-15 2010-03-09 University Of South Florida Methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20080183070A1 (en) * 2007-01-29 2008-07-31 Wisconsin Alumni Research Foundation Multi-mode medical device system with thermal ablation capability and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038086A1 (en) * 2000-07-27 2002-03-28 Hynynen Kullervo H. Blood-brain barrier opening
US20100172842A1 (en) * 2007-05-16 2010-07-08 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Assessment of blood-brain barrier disruption
US20110318431A1 (en) * 2008-12-30 2011-12-29 Endogenx Pharmaceutical Compositions and Methods of Treating Neurological Insults
US20130158387A1 (en) * 2010-08-30 2013-06-20 Koninklijke Philips Electronics N.V. Mri thermal imaging of water tissue and fat tissue using transverse relaxometry data and proton resonance frequency shift data

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROMAN-GOLDSTEIN, S. M. ET AL.: "Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings", AMERICAN JOURNAL OF NEURORADIOLOGY, vol. 12, 1991, pages 885 - 890, XP008175819 *

Also Published As

Publication number Publication date
US20170079581A1 (en) 2017-03-23
WO2015179258A2 (en) 2015-11-26
US10478120B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
WO2015179258A3 (en) Mri-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening
Obrig NIRS in clinical neurology—a ‘promising’tool?
WO2015092020A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
WO2012106514A3 (en) System and method for diagnosis and treatment
Suarez et al. Effect of human albumin on TCD vasospasm, DCI, and cerebral infarction in subarachnoid hemorrhage: the ALISAH study
WO2016133848A3 (en) Therapeutic angiogenesis for treating erectile conditions
WO2015176062A3 (en) Systems and methods of managing treatment of a chronic condition by symptom tracking
EA201490883A1 (en) APPLICATION OF ANTIBODIES TO α-SINUCULINE FOR DIAGNOSTIC OF THE INCREASED LEVEL OF α-SINUCLEIN IN THE BRAIN
NZ717595A (en) Methods and tools relating to the administration of contrast medium
EP3470091A4 (en) Non-invasive diagnostic imaging agent for heart disease
WO2014145357A3 (en) Improved methods of use for recombinant human secretoglobins
Mould et al. Minimally invasive surgery plus rt-PA for intracerebral hemorrhage evacuation (MISTIE) decreases perihematomal edema
Cho et al. What is your diagnosis? Rhino-orbital-cerebral mucormycosis
FR2999938B1 (en) INFUSION SYSTEM FOR ADMINISTERING A SOLUTION AND RINSING THE SAID SYSTEM
UA73891U (en) method for predicting the risk of ischemic cerebral blood flow
Liguori Ephedrine/naphazoline
Kim Ethambutol/isoniazid/pyridoxine/rifampicin
Wang et al. The comparison of diffusion and perfusion characteristics among the different types of uterine fibroids based on T2WIs: an intravoxel incoherent motion MRI study
Fukusumi Normal anatomy of intracranial veins: demonstration with MR angiography, 3D-CT angiography and microangiographic injection study
IL228405D0 (en) Methods of targeted treatment of frontotemporal lobar degeneration
陈超 Brain network modularity study in treating-na ve, first episode major depressive disorder
Madias Atypical global Takotsubo syndrome in a patient with acute disseminated encephalomyelitis
Aboian et al. 50.1 Uses
Aboian et al. Propofol
Niu et al. Combing fMRI and probabilistic DTI tractography to improve corticospinal tract visualization in patients with brain tumor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15796337

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15311696

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15796337

Country of ref document: EP

Kind code of ref document: A2